Agilent Technologies Total Revenue decreased by 3.4% to $1.80B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.0%, from $1.68B to $1.80B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows relatively stable performance with a 2.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenue| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.53B | $1.59B | $1.66B | $1.67B | $1.61B | $1.72B | $1.85B | $1.76B | $1.72B | $1.67B | $1.69B | $1.66B | $1.57B | $1.58B | $1.70B | $1.68B | $1.67B | $1.74B | $1.86B | $1.80B |
| QoQ Change | — | +4.0% | +4.7% | +0.8% | -4.0% | +6.9% | +7.6% | -5.0% | -2.2% | -2.6% | +1.0% | -1.8% | -5.1% | +0.3% | +7.8% | -1.2% | -0.8% | +4.2% | +7.1% | -3.4% |
| YoY Change | — | — | — | — | +5.4% | +8.3% | +11.4% | +4.9% | +6.8% | -2.7% | -8.7% | -5.6% | -8.4% | -5.6% | +0.8% | +1.4% | +6.0% | +10.1% | +9.4% | +7.0% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Services and Other | $448.00M | $457.00M | $484.00M | $481.00M | $482.00M | $508.00M | $533.00M | $525.00M |
| Total | $1.57B | $1.58B | $1.70B | $1.68B | $1.67B | $1.74B | $1.86B | $1.80B |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Agilent CrossLab | $402.00M | $411.00M | $426.00M | $696.00M | $713.00M | $744.00M | $755.00M | $758.00M |
| Life Sciences and Diagnostics Markets | — | — | — | $647.00M | $654.00M | $670.00M | $755.00M | $679.00M |
| Applied Markets | — | — | — | $338.00M | $301.00M | $324.00M | $351.00M | $361.00M |
| Diagnostics and Genomics | $417.00M | $385.00M | $442.00M | — | — | — | — | — |
| Life Sciences and Applied Markets | $754.00M | $782.00M | $833.00M | — | — | — | — | — |
| Total | $1.57B | $1.58B | $1.70B | $1.68B | $1.67B | $1.74B | $1.86B | $1.80B |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Americas | $637.00M | $626.00M | $680.00M | $669.00M | $678.00M | $683.00M | $776.00M | $678.00M |
| Asia Pacific | $510.00M | $520.00M | $567.00M | $549.00M | $548.00M | $563.00M | $559.00M | $602.00M |
| Europe | $426.00M | $432.00M | $454.00M | $463.00M | $442.00M | $492.00M | $526.00M | $518.00M |
| Total | $1.57B | $1.58B | $1.70B | $1.68B | $1.67B | $1.74B | $1.86B | $1.80B |